Bayer sent the market a clear operational signal this week by announcing the acquisition of US biotech Perfuse Therapeutics for up to $2.45 billion. The stock responded with a 4.35% leap to €37.42, its best single-day performance in months. Yet beneath the surface, the shareholder register tells a more conflicted story. Temasek, the Singaporean state fund, slashed its stake to 2.90% from 4.17% on June 8, falling below the mandatory disclosure threshold. Meanwhile, Goldman Sachs disclosed a position of 5.36%, including instruments, as some large investors eye the current market capitalisation of around €35.5 billion as a potential entry point.
The centrepiece of the deal is PER-001, a phase-II candidate targeting glaucoma and diabetic retinopathy. Bayer is paying $300 million upfront — a significant outlay given its ongoing balance-sheet constraints — with the remainder contingent on milestones. The move reflects a deliberate push into ophthalmology, a segment Bayer believes can deliver the next pharmaceutical blockbuster. Whether the bet pays off will depend on upcoming clinical data, but management is signalling that the pharma division is on the offensive rather than merely defending its legacy portfolio.
None of this dispels the legal shadow hanging over the stock. The US Supreme Court is expected to rule in June or early July on the Durnell glyphosate case, a decision analysts describe as nearly a coin toss. Berenberg puts Bayer’s odds of a favourable outcome at about 60%, projecting a share price rise toward €45 if the company wins, but a slide to around €30 if it loses. UBS, more bullish, maintains a target of €52 with a buy rating. That binary scenario keeps the stock in a holding pattern: before the Perfuse news, shares traded at €36.08, exactly on their 200-day moving average. The acquisition jump pushed them roughly 3.6% above that line, but they still sit more than 25% below the year’s high of €49.93.
Should investors sell immediately? Or is it worth buying Bayer?
Other operational developments are adding to the mix. The European Medicines Agency has begun a formal review of Bayer’s stroke drug Asundexian, while margins in the pharma unit are improving, helping to offset patent expiries on key products. The company’s new finance chief, Judith Hartmann, who took over at the start of June, faces the urgent task of reducing debt. Her room for manoeuvre, however, will be dictated by the Supreme Court’s verdict.
The divergence among major investors highlights the uncertainty. Temasek’s retreat offers no public explanation, but the reduction below the 3% threshold means future moves will no longer be reported. Goldman’s increased exposure, by contrast, suggests a strategic bet on a recovery. The 30-day volatility stands at 31.50%, reflecting the market’s struggle to price in both the operational improvements and the existential legal risk.
Bayer today is a stock pulled in two directions: an active corporate strategy that aims to build value through acquisitions and pipeline advances, and a single court case that could rewrite the entire narrative in a matter of weeks. The next few weeks will determine which force prevails.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 17 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 17.
Bayer: Buy or sell? Read more here...
